Citations

Clear

4847 citation(s) found for "Yu, Eric".

Validation and Disease Risk Assessment of Previously Reported Genome-Wide Genetic Variants Associated With Brugada Syndrome
Liu, Yen‐Bin , Chen, Ching‐Yu Julius, Yu, Qi-You , Chattopadhyay, Amrita , Lin, Lian-Yu, Chen, Wen‐Jone , Yu, Chih-Chien, Huang, Hui‐Chun , Liao, Min‐Tsun , Yeh, Shih-Fan Sherri, Chuang, Jing‐Yuan, Yang, Dun-Hui, Lin, Jiunn‐Lee, Lu, Tzu‐Pin , Ackerman, Michael J. , Juang, Jyh‐Ming Jimmy , Ho, Li‐Ting , Lai, Ling‐Ping , Hwang, Juey‐Jen , Lin, Ting‐Tse , Chen, Jien‐Jiun , Chuang, Eric Yao-Yu

Mayo Clinic

Circulation: Genomic and Precision Medicine | June 3, 2020 | Volume: 13 | Issue: 4 | Pages: No page available

10.1161/circgen.119.002797 | PMID 32490690 Get It

Background: Brugada syndrome (BrS) is an oligogenic arrhythmic disease with increased risk of sudden cardiac arrest. Several BrS or ECG traits-related single-nucleotide polymorphisms (SNPs) were identified through previous genome-wide association studies in white patients. We aimed to validate these SNPs in BrS patients in the Taiwanese population, assessing the cumulative effect of risk alleles and the BrS-polygenic risk score in predicting cardiac events. Methods: We genotyped 190 unrelated BrS patients using the TWB Array, and Taiwan Biobank was used as controls. SNPs not included in the array were imputed by IMPUTE2. Cox proportional hazards model was used to evaluate the associations between each particular SNP, the collective BrS-polygenic risk score, and clinical outcomes. Results: Of the 88 previously reported SNPs, 22 were validated in Taiwanese BrS patients ( P <0.05). Of the 22 SNPs, 2 (rs10428132 and rs9388451) were linked with susceptibility to BrS, 10 were SNPs previously reaching genome-wide significance, and 10 were SNPs associated with ECG traits. For the 3 most commonly reported SNPs, disease risk increased consistently with the number of risk alleles (odds ratio, 3.54; P trend =1.38×10 −9 for 5 risk alleles versus 1). Similar patterns were observed in both SCN5A mutation+ (odds ratio, 3.66; P trend =0.049) and SCN5A mutation− (odds ratio, 3.75; P trend =8.54×10 −9 ) subgroups. Furthermore, BrS patients without SCN5A mutations had more risk alleles than BrS patients with SCN5A mutations regardless of the range of polygenic risk scores. Three SNPs (rs4687718, rs7784776, and rs2968863) showed significant associations with the composite outcome (sudden cardiac arrest plus syncope, hazard ratio, 2.13, 1.48, and 0.41; P =0.02, 0.006, and 0.008, respectively). Conclusions: Our findings suggested that some SNPs associated with BrS or ECG traits exist across multiple populations. The cumulative risk of the BrS-related SNPs is similar to that in white BrS patients, but it appears to correlate with the absence of SCN5A mutations.
Long-term Outcomes of MCP Surface Replacement Arthroplasty in Patients With Rheumatoid Arthritis
Mohney, Brian G. , Rizzo, Marco , Claxton, Matthew R , Rizzo, Marco , Wagner, Eric R.

Mayo Clinic

HAND | June 3, 2020 | Volume: 17 | Issue: 2 | Pages: 271-277

10.1177/1558944720926631 | PMID 32486855 Get It

Background: Surface replacement arthroplasty (SRA) can be used in the treatment of rheumatoid arthritis (RA) affecting the metacarpophalangeal (MCP) joint. The authors of this study sought to investigate the outcomes of MCP SRA in patients with RA. Methods: Retrospective review of medical records and an institutional joint registry were used to gather data on 80 MCP SRAs performed in 27 patients with RA. Data collected included demographics, SRA revisions, reoperations, complications, pain, and MCP arc of motion. Results: The mean postoperative follow-up was 9.5 years (range, 2.1-20.5 years), with all SRAs achieving at least 2 years of follow-up. Thirteen digits (16%) underwent revision arthroplasty, and 29 (36%) required reoperation. The 5-, 10-, 15-, and 20-year rates of survival from implant revision were 95%, 85%, 80%, and 69%, respectively. The 5-, 10-, 15-, and 20-year rates of survival from overall reoperation were 80%, 65%, 55%, and 46%, respectively. Metacarpophalangeal joint arc of motion, grip strength, and pain levels significantly improved following surgery. Conclusions: Metacarpophalangeal SRA can offer benefit to patients with RA for improvement in function and pain. High overall reoperation rates remain concerning; however, most do not involve arthroplasty revision.
Infections or Sepsis Preceding Clinically Diagnosed α‐Synucleinopathies: A Case‐Control Study
Hasan, Shemonti , Ahlskog, J. Eric , Bower, James H., Turcano, Pierpaolo , Savica, Rodolfo , Savica, Rodolfo , Mielke, Michelle M.

Mayo Clinic

Movement Disorders | June 1, 2020 | Volume: 35 | Issue: 9 | Pages: 1684-1689

10.1002/mds.28111 | PMID 32479692 Get It

AbstractBackgroundSeveral studies have proposed a role for infections to induce an inflammatory response triggering Parkinson's disease. This remains controversial and the influence of severe infections on other α‐synucleinopathies (Dementia with Lewy Bodies, Parkinson's disease dementia, and Multiple System Atrophy) has not been adequately investigated.ObjectivesTo assess the association between hospitalization‐required infections or sepsis and risk of clinically diagnosed α‐synucleinopathies.MethodsUsing the medical records‐linkage system (Rochester Epidemiology Project), we identified all α‐synucleinopathy cases of in Olmsted County (1991–2010). Cases were matched by symptom‐onset age and sex to controls. We reviewed complete medical records to detect hospital‐required infections or sepsis preceding clinical‐motor onset of α‐synucleinopathies. We used conditional logistic regression to calculate the odds ratio of all α‐synucleinopathies, adjusting for medications, coffee, and smoking.ResultsThere was no association between infection‐related hospitalization (odds ratio: 1.05; 95% confidence interval: 0.78–1.40; P = 0.76) or sepsis (odds ratio: 0.86; 95% confidence interval: 0.40–1.85; P = 0.70) and all α‐synucleinopathies in multivariable analyses. We did not identify any associations after stratifying for type of α‐synucleinopathy, sex, and age at clinical‐motor onset. We analyzed sepsis separately with similar results.ConclusionWe did not observe any associations between infections leading to hospitalization or sepsis and development of any α‐synucleinopathies. © 2020 International Parkinson and Movement Disorder Society
Results of proximal interphalangeal arthroplasty: border digits versus middle digits
Barras, Laurel A. , Fort, Michael W. , Robinson, William A. , Rizzo, Marco , Robinson, William, Wagner, Eric R.

Mayo Clinic

Journal of Hand Surgery (European Volume) | June 1, 2020 | Volume: 45 | Issue: 7 | Pages: 709-714

10.1177/1753193420926127 | PMID 32475206 Get It

This investigation assessed 106 consecutive primary proximal interphalangeal joint arthroplasties performed on border digits: 73 index or 33 little fingers. This was compared with 193 arthroplasties performed in non-border digits: 121 middle or 72 ring fingers. There were 20 proximal interphalangeal joint arthroplasties in the border digits that required revision surgery for pain and stiffness (10 digits), dislocation (six digits), implant fracture (one digit), and infection (three digits). Risk of revision surgery was not associated with border digit. The 5-year implant survival rate for the border digits was 81%. There was no significant difference in implant revision rate or joint dislocations between border and non-border digits. We conclude that proximal interphalangeal joint arthroplasties performed in border digits had similar pain relief, survivorship, complications, and reoperation rates compared with those performed in non-border digits. Level of evidence: IV
Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial
Brown, Sue A. , Beck, Roy W. , Raghinaru, Dan, Buckingham, Bruce A. , Laffel, Lori M. , Kudva, Yogish C. , Pinsker, Jordan E. , Dassau, Eyal , Ambler-Osborn, Louise, Anderson, Stacey M. , Church, Mei Mei , Ekhlaspour, Laya , Forlenza, Gregory P. , Levister, Camilla, Simha, Vinaya , Breton, Marc D. , Kollman, Craig, Lum, John W. , Kovatchev, Boris , Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Gondor-Fredrick, Linda, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Isganaitis, Elvira , Flint, Emily, Kim, Kenny, Roethke, Lindsay, André, Camille , Piper, Molly, Lam, David W. , O’Malley, Grenye , Ogyaadu, Selassie, Lovett, Jessica, Dadlani, Vikash, McCrady-Spitzer, Shelly , Reid, Corey, Slover, Robert H., Jost, Emily , Berget, Cari , Towers, Lindsey, Rossick-Solis, Alex, Jacobson, Tali, Town, Marissa, Tabatabai, Ideen , Keller, Jordan, Salas, Evalina, Passman, Samantha, Campos, Tiffany, Murphy, Carlos, Patibandla, Nandan, Borgman, Sarah, Arreza-Rubin, Guillermo, Eggerman, Thomas L., Green, Neal, Reznik, Yves , Janicek, Robert, Gabrielson, Deanna, Belle, Steven H., Castle, Jessica R. , Legault, Laurent , Wysham, Carol , Kudva, Yogish C. , Pinsker, Jordan E , Dassau, Eyal , Doyle, Francis J , Ekhlaspour, Laya , Forlenza, Gregory P , Breton, Marc D , Lum, John , Kovatchev, Boris , Buckingham, Bruce , Beck, Roy W , Wadwa, R Paul , Levy, Carol J. , Doyle, Francis J. , Kollman, Craig , Oliveri, Mary Clancy , Kumari, Kanchan , Alonso, G. Todd , Messer, Laurel H , Renard, Eric , Cobelli, Claudio , Green, Jennifer Greif , Willi, Steven Matthew

Mayo Clinic

Diabetes Care | May 30, 2020 | Volume: 43 | Issue: 8 | Pages: 1822-1828

10.2337/dc20-0124 | PMID 32471910 Get It

OBJECTIVE Limited information is available about glycemic outcomes with a closed-loop control (CLC) system compared with a predictive low-glucose suspend (PLGS) system. RESEARCH DESIGN AND METHODS After 6 months of use of a CLC system in a randomized trial, 109 participants with type 1 diabetes (age range, 14–72 years; mean HbA1c, 7.1% [54 mmol/mol]) were randomly assigned to CLC (N = 54, Control-IQ) or PLGS (N = 55, Basal-IQ) groups for 3 months. The primary outcome was continuous glucose monitor (CGM)-measured time in range (TIR) for 70–180 mg/dL. Baseline CGM metrics were computed from the last 3 months of the preceding study. RESULTS All 109 participants completed the study. Mean ± SD TIR was 71.1 ± 11.2% at baseline and 67.6 ± 12.6% using intention-to-treat analysis (69.1 ± 12.2% using per-protocol analysis excluding periods of study-wide suspension of device use) over 13 weeks on CLC vs. 70.0 ± 13.6% and 60.4 ± 17.1% on PLGS (difference = 5.9%; 95% CI 3.6%, 8.3%; P &lt; 0.001). Time &gt;180 mg/dL was lower in the CLC group than PLGS group (difference = −6.0%; 95% CI −8.4%, −3.7%; P &lt; 0.001) while time &lt;54 mg/dL was similar (0.04%; 95% CI −0.05%, 0.13%; P = 0.41). HbA1c after 13 weeks was lower on CLC than PLGS (7.2% [55 mmol/mol] vs. 7.5% [56 mmol/mol], difference −0.34% [−3.7 mmol/mol]; 95% CI −0.57% [−6.2 mmol/mol], −0.11% [1.2 mmol/mol]; P = 0.0035). CONCLUSIONS Following 6 months of CLC, switching to PLGS reduced TIR and increased HbA1c toward their pre-CLC values, while hypoglycemia remained similarly reduced with both CLC and PLGS.
Effect of ApoE isoforms on mitochondria in Alzheimer disease
Yin, Junxiang , Reiman, Eric M. , Beach, Thomas G. , Nielsen, Megan , Caselli, Richard J. , Shi, Jiong , Shi, Jiong , Serrano, Geidy E. , Sabbagh, Marwan Noel

Mayo Clinic

Neurology | May 27, 2020 | Volume: 94 | Issue: 23 | Pages: No page available

10.1212/wnl.0000000000009582 | PMID 32457210 Get It

Multi‐energy computed tomography and material quantification: Current barriers and opportunities for advancement
Jacobsen, Megan C. , Thrower, Sara , Court, Laurence E. , Tamm, Eric P. , Cody, Dianna D. , Layman, Rick R. , Thrower, Sara , Ger, Rachel , Leng, Shuai , Brock, Kristy K. , Cressman, Erik N. K.

Mayo Clinic

Medical Physics | May 26, 2020 | Volume: 47 | Issue: 8 | Pages: 3752-3771

10.1002/mp.14241 | PMID 32453879 Get It

Computed tomography (CT) technology has rapidly evolved since its introduction in the 1970s. It is a highly important diagnostic tool for clinicians as demonstrated by the significant increase in utilization over several decades. However, much of the effort to develop and advance CT applications has been focused on improving visual sensitivity and reducing radiation dose. In comparison to these areas, improvements in quantitative CT have lagged behind. While this could be a consequence of the technological limitations of conventional CT, advanced dual‐energy CT (DECT) and photon‐counting detector CT (PCD‐CT) offer new opportunities for quantitation. Routine use of DECT is becoming more widely available and PCD‐CT is rapidly developing. This review covers efforts to address an unmet need for improved quantitative imaging to better characterize disease, identify biomarkers, and evaluate therapeutic response, with an emphasis on multi‐energy CT applications. The review will primarily discuss applications that have utilized quantitative metrics using both conventional and DECT, such as bone mineral density measurement, evaluation of renal lesions, and diagnosis of fatty liver disease. Other topics that will be discussed include efforts to improve quantitative CT volumetry and radiomics. Finally, we will address the use of quantitative CT to enhance image‐guided techniques for surgery, radiotherapy and interventions and provide unique opportunities for development of new contrast agents.
Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816
Ha, Chul S. , Pinnix, Chelsea C. , Bartlett, Nancy L. , Evens, Andrew M. , Knopp, Michael V. , Leonard, John P. , Smith, Sonali M. , Friedberg, Jonathan W. , Zhang, Jun , Pinnix, Chelsea C , Bartlett, Nancy L , Rimsza, Lisa, Evens, Andrew M , LeBlanc, Michael , Schöder, Heiko , Hsi, Eric D. , Rimsza, Lisa M. , Zhang, Jun , Kahl, Brad S. , Li, Hongli , Constine, Louis S

Mayo Clinic

Leukemia & Lymphoma | May 26, 2020 | Volume: 61 | Issue: 10 | Pages: 2442-2447

10.1080/10428194.2020.1768388 | PMID 32452714 Get It

Work loss and activity impairment due to duration of nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.
Navari, Rudolph M. , Ruddy, Kathryn J. , Clark-Snow, Rebecca, Wickham, Rita S., Binder, G. , Bailey, William L., Turini, Marco, Schmerold, Luke, Schwartzberg, Lee Steven , LeBlanc, Thomas W. , Potluri, Ravi C. , Roeland, Eric

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: e24133-e24133

10.1200/jco.2020.38.15_suppl.e24133 Get It

e24133 Background: The impact of chemotherapy-induced nausea and vomiting (CINV) on work loss and activity impairment is important to patients yet not well described in literature. We sought to evaluate CINV-related work loss and activity impairment and their associations with CINV duration. Methods: In a prospective CINV prophylaxis trial of oral or intravenous netupitant/palonestron (NEPA) + dexamethasone (DEX) (12mg day 1 only) for patients with breast cancer receiving anthracycline + cyclophosphamide (AC), we defined CINV as vomiting or use of rescue medication during days 1-5 after AC. Pre-specified endpoints included CINV duration (0-5 days), patient reported CINV-associated work loss (Work Productivity and Activity Impairment survey), and CINV-related impaired activity [0 (none) - (worst) Likert scale] for chemotherapy cycles 1 and 2. CINV-related work loss and activity impairment could involve nausea with or without vomiting or rescue medication use. We categorized CINV duration as 1-2 days (d) or ≥3 d, and compared results using the chi-squared test. We report here on the first 2 cycles. Results: Survey data was captured for 792 cycles in 402 female patients including 132 (32.8%) employed patients. Mean age was 55.4. CINV was observed in 173 (21.8%) of total cycles. CINV-related work loss was reported in 26 (3.3% of all cycles, 15.0% of cycles with CINV, 38.2% of employed patient cycles with CINV) while 142 had related activity impairment. When we categorized cycles by CINV duration, CINV-related work loss was seen in 25.9% of 81 cycles with ≥3 d CINV duration vs. 5.4% for 92 cycles of 1-2 d of CINV (p < 0.001); mean scores of CINV-related impaired activity were 5.0 for ≥3 d CINV vs 3.0 for 1-2 d CINV (p < 0.001). Conclusions: Despite guideline recommended prophylaxis, CINV occurred in > 20% of AC cycles. In cycles with CINV, CINV-related work loss occurred in 38.2% for employed patients while activity impairment occurred in 82.1% for all patient cycles. The majority of CINV lasted 1-2 d. Notably, ≥3 d of CINV was associated with considerably higher levels of work loss and activity impairment suggesting that duration may be a meaningful measure of CINV impact. Clinical trial information: NCT03403712 . [Table: see text]
Integrating pharmacogenomics panel testing for supportive care medications in patients with solid tumors.
Kekić, Adrijana, Seetharam, ­Mahesh , Golafshar, Michael A. , Azevedo, Cindy, Welp, Sydney, Bofferding, Anne, Koep, Tyler, Ross, Jason , Nelson, Eric C. , Grilli, Christopher, Samadder, Jewel, Golafshar, Michael , Singh, Parminder Pal , Kunze, Katie L.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: e24114-e24114

10.1200/jco.2020.38.15_suppl.e24114 Get It

e24114 Background: Pharmacogenomics (PGx) testing is used increasingly in cancer supportive care for drug and dose selection, and side effects prediction with antidepressants, antiemetics, and pain medications. Genetic variants in genes that encode for drug metabolizing enzymes (CYPs), transporters (SLC6A4) and drug receptors (HTR2A, OPRM1, etc) are well known for these medications. They contribute to inter-individual differences in medication safety and efficacy. We report on their frequency and effect on supportive care drugs in patients with solid tumors. Methods: Between 06/06/19 and 12/18/19, solid tumor cancer patients at Mayo Clinic Arizona were enrolled in a PGx prospective study. They were genotyped using a multi-gene panel, OneOme RightMed. The panel assessed 27 genes, including CYP2C9, CYP2C19, CYP2D6, CYP3A4, COMT, OPRM1, GRIK4, HTR2A, SLC6A4, associated with pain medications, antidepressants, and antiemetics. PGx pharmacist provided medication recommendations and dose adjustments based on PGx test results and concurrent medications. Results: 200 patients were swabbed and 196 patients were genotyped. The results were available within 5 days. All patients were also assessed for pheno-conversion (drug-drug-gene interactions) by a pharmacist. Recommendations were made based on predicted phenotype. Various solid tumor types were represented, including prostate (19.9%), colorectal (17.9%), melanoma (14.8%), and others (47.4%). Median age was 65 with 59.2% patients being male and 40.85% female. All had at least one actionable polymorphism related to these medications. The most significant findings were related to CYP2C19 and CYP2D6 genes. Of 196 patients, a total of 132 (67.3%) had other than normal CYP2D6 metabolizer phenotype and 112 (57.1%) had other than normal CYP2C19 metabolizer phenotype. Based on these genotypes, alternatives to pain medications were recommended for 37 patients, to ondansetron in 9 patients, and to anti-depressants in 51 patients. Conclusions: Genetic variants were commonly found that affect supportive care medications used in oncology practice and contribute to inter-individual differences associated with increased risk of adverse drug effects and reduced efficacy. PGx guided recommendation may help physicians in individualizing medication treatment outcomes for patients with different cancer types and with polypharmacy. PGx trained pharmacist can serve as a valuable asset in optimizing personalized medication management.